Can you genuinely delay knee replacement — and by how much?

For most people with knee osteoarthritis, surgery is not an immediate inevitability. Non-surgical management — done properly, and matched to the right patient — can push the need for a total knee replacement back by years rather than months, and in milder disease the window may extend further still. The scale of benefit depends on how far the joint has already deteriorated: mild-to-moderate cartilage wear is far more amenable to long-term conservative management than end-stage bone-on-bone degeneration, where non-surgical options tend to provide only limited postponement.

There is a clear clinical logic behind the push to delay. Roughly 85% of knee prostheses last 20 years, and the AAOS estimates around 10% of patients will need revision surgery at some point. Revision operations rarely restore function as fully as the original procedure, and the younger a patient is at first surgery, the more likely they are to outlive their implant. That calculus — not mere reluctance — is why NICE guideline NG226 and NHS guidance both require that exercise, weight management, and other non-surgical treatments be tried before a surgical referral is considered.

The evidence for delay is real, but it is also conditional. The sections below set out what the data actually show for each main intervention — without overstating what conservative care can reliably deliver.

Physical therapy: the most robust delay tool

Structured physiotherapy stands out as the most robustly evidenced strategy for keeping patients out of the operating theatre. A 2023 review by Surakanti, published in PMC, found that supervised PT delayed total knee arthroplasty in up to 95% of patients who received it — meaning the majority had not proceeded to surgery by the end of the study observation period, which extended across several months to years depending on enrolment timing. The figure reflects avoidance during follow-up rather than a permanent cure, but it is a meaningful signal about what a structured programme can achieve.

The emphasis on supervised PT matters. The evidence points to programmes that include a structured combination of strengthening, aerobic conditioning, and neuromuscular work, delivered by a physiotherapist — not self-directed stretching. How much each individual component contributes remains a genuine gap in the literature: the relative benefit of, say, quadriceps-loading exercise versus manual therapy has not been cleanly disaggregated across trials.

In a direct 2020 NEJM comparison — Deyle and colleagues, 156 participants — patients who received physiotherapy reported significantly less pain and functional disability at one year than those who received a single glucocorticoid injection. This head-to-head result is important clinically, since corticosteroid injection is often used as a first response to flares.

A separate cohort study adds a counterintuitive finding: among patients with meniscal damage and co-existing OA, those who underwent knee arthroscopy were 30% more likely to progress to joint replacement at any given time compared with those who had PT alone (hazard ratio 1.30; 95% CI 1.17–1.44). Choosing physiotherapy over opportunistic arthroscopy, in other words, may actively protect against earlier surgery — not merely defer it.

NICE guideline NG226 codifies this position, placing therapeutic exercise at the core of first-line management before any surgical referral is considered.

Injections: what HA and PRP realistically offer

Injection-based treatment sits at a different point on the delay spectrum from physiotherapy — useful as adjuncts, but bounded by what the data actually shows for each agent.

Hyaluronic acid: incremental but real

For hyaluronic acid (HA) viscosupplementation, the most informative dataset comes from a French cohort study of 14,782 patients with knee OA. At each time point measured — one year, three years, five years, and 7.5 years — patients who received HA injections went longer without requiring total knee replacement than controls. The additional time gained ranged from 51 to 217 days, with the advantage widening at longer follow-up. Statistically significant at every interval (p<0.001), the benefit is nonetheless incremental: a few months, not years. The clinical value is real, but realistic — HA may ease pain enough to support better physiotherapy adherence or create breathing room for structured weight loss, rather than acting as a standalone delay strategy.

PRP: striking figures, prospective validation still awaited

Platelet-rich plasma injections produce more striking delay figures. In a retrospective survival analysis by Sánchez and colleagues (2021), 74.1% of patients avoided total knee arthroplasty for more than 1.5 years, with a median delay of 5.3 years. That is a considerably longer horizon than HA data suggests. The important caveat is that this evidence is retrospective — without long-term randomised trial data, the 5.3-year median is best read as an indicative signal rather than a confirmed benchmark.

Both agents are most appropriately used as part of a structured conservative programme alongside physiotherapy and weight management, where they may reduce symptom burden and support adherence to the wider strategy.

Weight loss: when it moves beyond symptom relief

Losing weight reduces load on the knee joint — but that framing undersells what the evidence actually shows at sufficient magnitude. The more significant finding is that weight loss, above a certain threshold, appears to act on the disease process itself rather than merely dampening symptoms.

A 2024 network meta-analysis drawing on 13 randomised controlled trials and 2,800 participants found that reducing body weight by at least 7% is the point at which significant pain relief becomes reliably predictable in overweight or obese patients with knee OA. Below that threshold, results are inconsistent. Combined diet-plus-exercise programmes outperformed all single-intervention approaches for both weight reduction and pain outcomes — useful context for patients weighing whether dietary change alone is sufficient.

The mechanistic picture becomes clearer from a four-year Osteoarthritis Initiative cohort study: patients who lost more than 5% of body weight had significantly lower odds of higher-grade synovitis (OR 0.72; 95% CI 0.54–0.95), and mediation analysis showed that this reduction in joint inflammation partially explains the protective effect on cartilage degeneration. This is not incidental — it reframes weight loss from load-management into a route through which inflammation is reduced and cartilage breakdown slows, which is a meaningfully different clinical category.

GLP-1 receptor agonists such as semaglutide are attracting attention as a pharmacological route to weight loss that may carry additional anti-inflammatory properties in OA. The mechanistic hypothesis is plausible, and early data are encouraging, but arthroplasty-specific delay evidence remains pre-confirmatory — this is a promising avenue rather than an established strategy.

One practical note of caution: a 2025 review highlights that rapid or unsupervised weight loss carries genuine risks for people with OA — including joint destabilisation, sarcopenia, and reduced bone density. Supervised programmes that preserve muscle mass while achieving the ≥7% target are the preferable approach.

When delay crosses into harm

Delay is not a cost-free strategy at every stage of the disease. Clinical research has found that 55.49% of patients who postpone total knee surgery experience increased joint pain over the delay period — a figure that makes plain the trade-off: for many patients, waiting longer does not mean living more comfortably in the interim.

The structural consequences of prolonged delay extend beyond pain. As cartilage loss advances, joint anatomy changes: bone deformity worsens, surrounding musculature weakens through disuse, and scar tissue accumulates. The practical result is a more technically demanding operation, a longer rehabilitation, and functional outcomes constrained by how far the joint deteriorated before surgery took place. What was lost during that window cannot always be recovered — clinical experience documents cases in which distorted anatomy and established scarring permanently limited what the surgery could achieve.

The risk is not uniformly distributed across age groups. Younger patients face the greatest revision risk if surgery is performed early, which is precisely why the case for exhausting conservative options is strongest for them — the calculus of delay makes genuine clinical sense. Older patients with advanced disease sit at a different point in that calculation. At the threshold of end-stage bone-on-bone degeneration, non-surgical management tends to deliver only brief symptom relief rather than meaningful structural protection, and the cumulative quality-of-life cost of continued delay may outweigh the benefit of postponement.

The signal that delay has run its course is usually functional rather than radiological: persistent loss of mobility or quality of life that conservative measures can no longer meaningfully address.

Reading the signals: when non-surgical management has run its course

Three practical markers help clarify when a delay strategy has genuinely reached its ceiling. Persistent night pain — discomfort that interrupts sleep rather than arising only with movement — is one of the clearest functional signals. Inability to complete ordinary daily tasks such as climbing stairs, walking a short distance, or rising from a chair without significant limitation is another. The third is having worked through two or more sustained non-surgical approaches — not isolated injections or brief physiotherapy courses, but a structured, multi-modal programme given proper time across weeks to months — without achieving adequate relief.

That third marker matters because a single treatment failing is not a ceiling. One corticosteroid injection producing only transient benefit does not exhaust the conservative pathway. The picture changes when a genuinely combined programme of physiotherapy, weight management, and appropriate adjunct support still leaves function unacceptably compromised after a reasonable trial period.

Seeking specialist re-evaluation at that point is not the same as accepting surgery. A thorough assessment may identify a gap in the current plan, a biologic option not yet explored, or a modification to the rehabilitation approach that shifts the trajectory. Sometimes it confirms that replacement is now the right route. The purpose of that conversation is to determine which — and that determination rests on individual clinical grounds: disease severity, age, functional status, and the depth of the non-surgical trial already completed. Those are precisely the factors the evidence throughout this article has shown to matter most.

1. [1] Knee replacement - NHS. https://www.nhs.uk/conditions/knee-replacement/ https://www.nhs.uk/conditions/knee-replacement/
2. [2] Does Knee Arthroscopy for Treatment of Meniscal Damage with Osteoarthritis Delay Knee Replacement Compared to Physical Therapy Alone?. (2020). https://doi.org/10.4055/cios19114 https://doi.org/10.4055/cios19114
3. [3] Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis – A Cox model analysis. (2017). https://doi.org/10.1371/journal.pone.0187227 https://doi.org/10.1371/journal.pone.0187227
4. [4] Platelet-rich plasma injections delay the need for knee arthroplasty: a retrospective study and survival analysis. (2020). https://doi.org/10.1007/s00264-020-04669-9 https://doi.org/10.1007/s00264-020-04669-9
5. [5] Comparison of weight loss interventions in overweight and obese adults with knee osteoarthritis: a systematic review and network meta-analysis. (2024). https://doi.org/10.1016/j.joca.2024.08.012 https://doi.org/10.1016/j.joca.2024.08.012
6. [6] Glucagon-Like Peptide Receptor-1 Agonists in Patients With Hip and Knee Osteoarthritis (2024). (2024). https://doi.org/10.1016/j.artd.2024.101327 https://doi.org/10.1016/j.artd.2024.101327
7. [7] Synovitis mediates cartilage outcomes during weight-loss in knee osteoarthritis – 4-year follow-up data from the Osteoarthritis Initiative. (2025). https://doi.org/10.1016/j.ocarto.2025.100653 https://doi.org/10.1016/j.ocarto.2025.100653
8. [8] Weight Loss, but Not at Any Cost: Risks and Challenges in Patients with Osteoarthritis. (2025). https://doi.org/10.31138/mjr.121224.wlc https://doi.org/10.31138/mjr.121224.wlc